The U.S. Food and Drug Administration has approved an extended-release version of the twice-a-day canine incontinence drug Proin.
Given daily, Proin ER (phenylpropanolamine hydrochloride extended-release) tablets are indicated for the control of urinary incontinence due to urethral sphincter hypotonus in dogs.
The new prescription medication, manufactured by Pegasus Laboratories Inc., comes in 18-, 38-, 74- and 145-milligram tablets.
A clinical field study found the most common adverse reactions to be vomiting, body weight loss, hypertension and diarrhea, according to the FDA. The drug should not be given to dogs weighing less than 10 pounds.
Original Proin received FDA approval in 2011.